ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016 ACR/ARHP Annual Meeting
    • 2015 ACR/ARHP Annual Meeting
    • 2014 ACR/ARHP Annual Meeting
    • 2013 ACR/ARHP Annual Meeting
    • 2012 ACR/ARHP Annual Meeting
    • 2011 ACR/ARHP Annual Meeting
    • 2010 ACR/ARHP Annual Meeting
    • 2009 ACR/ARHP Annual Meeting
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1605

Post-Marketing Experience With Belimumab In U.S. Lupus Centers: Data From The Lupus Clinical Trials Consortium, Inc. (LCTC) National Patient Registry

Jinoos Yazdany1, Doruk Erkan2, Jorge sanchez-Guerrero3, Bevra H. Hahn4, Alana B. Levine2, Galina Marder5, W. Joseph McCune6 and Ellen M. Ginzler7, 1Medicine, University of California, San Francisco, San Francisco, CA, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada, 4Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 5Medicine, North Shore Long Island Health System, Great Neck, NY, 6Int Med/ Rheum, University of Michigan, Ann Arbor, MI, 7Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Lupus, registries and treatment

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Systemic Lupus Erythematosus - Clinical Aspects II: Central Nervous System Manifestations, Therapeutics

Session Type: Abstract Submissions (ACR)

Background/Purpose:  Much of the published experience with belimumab in lupus patients has derived from clinical trials.   We examined the non-sponsored experience with belimumab in routine clinical practice among 15 U.S. lupus centers participating in a national patient registry, the Lupus Clinical Trials Consortium, Inc. (LCTC).

Methods:  The LCTC registry consists of consecutively enrolled adults with SLE from U.S. centers, each contributing approximately 100 patients.  Patients who received at least one belimumab infusion after enrollment in the registry between March 2011, the date of FDA approval, and April 2013 were analyzed.  We investigated clinical characteristics, indications for belimumab, and reasons for discontinuation.  We calculated changes in SELENA-SLEDAI, physician global assessment, glucocorticoid dose, and serological parameters between baseline and follow-up at 6 months and 1 year for those maintained on the drug.

Results:  Among 1189 patients followed for 27,469 months (mean 23.2 months), 68 patients started belimumab (5.7%).  Mean treatment duration was 13.2 months (SD 6.7).  Three centers started no patients on the drug, and the remaining started between 1-5 patients.   In the 68 treated patients, mean age was 39.1 years (SD 12), 94% were female, 41% Caucasian, 47% Black and 12% Hispanic.  Mean disease duration was 10.7 years (SD 8).  Mean SELENA-SLEDAI at drug initiation was 4.4 (SD 4.3, range 0-22).  30 patients (44%) had a positive dsDNA upon starting belimumab and 15 (22%) had low complements.  The mean physician global assessment was 1.4 on a scale of 0-3 (SD 0.7).  56 patients (82%) were on glucocorticoids, with a mean prednisone dose of 14.6 mg (SD 23).  27% received azathioprine, 31% mycophenolate mofetil, 15% methotrexate, and 75% an anti-malarial.  The most common reasons for belimumab initiation were arthritis (52%), mucocutaneous disease (19%), and serositis (8%).   12 patients received the drug solely for maintenance, and 4 solely for steroid-sparing.  After 898 person-months of follow-up, 18 patients discontinued belimumab (4 for adverse events/intolerability, 3 lack of efficacy, 3 no longer needed it, 3 patient preference, and 1 for insurance reasons).  Response at 6 months and 1 year for those maintained on belimumab is shown in the Table.

Conclusion :   Since the approval of belimumab, 5.7% of patients enrolled in the LCTC registry have received the drug in routine clinical practice.  Utilization was similar across centers; the primary indications were arthritis and mucocutaneous disease.   After 6 and 12 months, there were statistically significant improvements in SELENA- SLEDAI and physician global assessment.  There was no statistically significant steroid-sparing effect.  65% of patients remained on belimumab by one year. 

The authors thank and acknowledge the Lupus Clinical Trials Consortium, Inc. (LCTC). The views expressed in this report are those of the authors and LCTC is not responsible for its specific content.

Table. Serological and lupus progression characteristics at treatment initiation, 6 months, and 12 months following belimumab administration among 68 patients.

Belimumab initiation

Six month follow-up

One year follow-up

N

68

58

44

Mean SELENA-SLEDAI (N)

68

58

44

   Mean ± SD

4.40±4.32

3.09±3.41*

2.30±2.79**

Mean physician global assessment (N)

62

51

37

   Mean ± SD

1.35±0.67

0.91±0.71*

0.78±0.72**

Prednisone equivalent dose (N)

55

45

33

   Mean ± SD

17.8±23.7

14.4±15.6

16.0±27.9

C3** (N)

64

54

40

   Mean ± SD

22.8±28.5

23.7±32.2

31.5±42.2*

   Low (%)

60 (93.8)

49 (90.7)

34 (94.4)

   Returned to normal from prior 6 months

–

2/47 (4.3)

2/36 (5.6)

C4** (N)

63

54

41

   Mean ± SD

7.1±9.2

7.6±11.5

9.1±13.8

   Low (%)

51 (81.0)

45 (83.3)

32 (94.1)

   Returned to normal from prior 6 months

–

1/39 (2.6)

2/34 (5.9)

Anti ds-DNA** (N)

62

41

26

   Positive (%)

30 (48.4)

22 (53.7)

13 (50.0)

   Became negative from last follow-up (%)

–

1/20 (5.0)

1/12 (8.3)

P values are two-tailed and represent results of paired t-tests.

* p< 0.05, ** p<0.01,

**C3, C4, and anti-dsDNA results reflect available data collected +/-3 months of each time point examined.

Note:  Because the components of the British Isles Lupus Assessment Group Index (BILAG) was not collected, the BILAG it is not presented here and the SLE responder Index or SRI could not be calculated


Disclosure:

J. Yazdany,
None;

D. Erkan,

GlaxoSmithKline,

8;

J. sanchez-Guerrero,

GlaxoSmithKline,

5,

Bristol-Myers Squibb,

5,

Biogen Idec,

5,

Genentech and Biogen IDEC Inc.,

5;

B. H. Hahn,

Eli Lilly and Company,

5,

Biogen-IDEC,

5,

Astella Pharma ,

5,

Teva Pharmaceutical,

2;

A. B. Levine,
None;

G. Marder,
None;

W. J. McCune,
None;

E. M. Ginzler,

GlaxoSmithKline,

2.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/post-marketing-experience-with-belimumab-in-u-s-lupus-centers-data-from-the-lupus-clinical-trials-consortium-inc-lctc-national-patient-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Annual Meeting in Atlanta, Georgia

© COPYRIGHT 2019 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.